Pacific Biosciences Of California (PACB) Total Current Liabilities (2010 - 2026)

Pacific Biosciences Of California's Total Current Liabilities history runs 17 years deep, the most recent figure standing at $65.4 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 1.87% year-over-year to $65.4 million in Q1 2026; TTM through Mar 2026 was $65.4 million, a 1.87% decrease from a year earlier, with the FY2025 full-year figure at $72.8 million, up 9.85% from the prior year.
• Total Current Liabilities retreated to $65.4 million in Q1 2026 per PACB's latest filing, from $72.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $271.4 million in Q2 2023 and bottomed at $59.8 million in Q2 2025.
• The 5-year median for Total Current Liabilities is $73.0 million (2024), against an average of $112.5 million.
• Across the five-year window, Total Current Liabilities surged 335.46% in 2023 and slumped 72.54% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $263.3 million in 2022, then sank by 63.91% to $95.0 million in 2023, then tumbled by 30.23% to $66.3 million in 2024, then gained by 9.85% to $72.8 million in 2025, then declined by 10.26% to $65.4 million in 2026.
• Per Business Quant, the three latest PACB Total Current Liabilities figures stand at $65.4 million (Q1 2026), $72.8 million (Q4 2025), and $63.2 million (Q3 2025).